These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10888032)

  • 1. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
    Fry DW
    Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
    Fry DW
    Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
    Ang KK; Andratschke NH; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers.
    O'Rourke DM; Zhang X; Greene MI
    Proc Assoc Am Physicians; 1997 May; 109(3):209-19. PubMed ID: 9154637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of HKI-272 and related compounds for the treatment of cancer.
    Wissner A; Mansour TS
    Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A; Crombet T; González G
    Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
    Hubbard RD; Bamaung NY; Fidanze SD; Erickson SA; Palazzo F; Wilsbacher JL; Zhang Q; Tucker LA; Hu X; Kovar P; Osterling DJ; Johnson EF; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1718-21. PubMed ID: 19217287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB family targeting.
    Black JD; Brattain MG; Krishnamurthi SA; Dawson DM; Willson JK
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1451-4. PubMed ID: 14763131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
    Khalil MY; Grandis JR; Shin DM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S; Ostman A; Rollman O
    Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.